Information Provided By:
Fly News Breaks for August 5, 2016
LGND
Aug 5, 2016 | 05:59 EDT
Deutsche Bank analyst Gregg Gilbert downgraded Ligand Pharmaceuticals to Sell saying the risk/reward is "challenging" at current share levels. The analyst sees potential downside from current levels if revenue momentum does not continue or if new pipeline "upsides" do not emerge. Following Ligand's Q2 results, Gilbert raised his price target for the shares to $110 from $104.
News For LGND From the Last 2 Days
There are no results for your query LGND